206 related articles for article (PubMed ID: 28210286)
1. Bilastine in allergic rhinoconjunctivitis and urticaria: a practical approach to treatment decisions based on queries received by the medical information department.
Leceta A; Sologuren A; Valiente R; Campo C; Labeaga L
Drugs Context; 2017; 6():212500. PubMed ID: 28210286
[TBL] [Abstract][Full Text] [Related]
2. Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions.
Leceta A; García A; Sologuren A; Campo C
Drugs Context; 2021; 10():. PubMed ID: 34457015
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria.
Church MK
Expert Opin Drug Saf; 2011 Sep; 10(5):779-93. PubMed ID: 21831011
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria.
Rodríguez M; Vozmediano V; García-Bea A; Novák Z; Yáñez A; Campo C; Labeaga L
Eur J Pediatr; 2020 May; 179(5):801-805. PubMed ID: 31919579
[TBL] [Abstract][Full Text] [Related]
5. Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving.
Jáuregui I; Ramaekers JG; Yanai K; Farré M; Redondo E; Valiente R; Labeaga L
Expert Opin Drug Saf; 2016 Jan; 15(1):89-98. PubMed ID: 26571227
[TBL] [Abstract][Full Text] [Related]
6. Bilastine: a lifetime companion for the treatment of allergies.
Church MK; Tiongco-Recto M; Ridolo E; Novák Z
Curr Med Res Opin; 2020 Mar; 36(3):445-454. PubMed ID: 31612732
[No Abstract] [Full Text] [Related]
7. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review.
Bousquet J; Ansótegui I; Canonica GW; Zuberbier T; Baena-Cagnani CE; Bachert C; Cruz AA; González SN; Kuna P; Morais-Almeida M; Mullol J; Ryan DP; Sánchez-Borges M; Valiente R; Church MK
Curr Med Res Opin; 2012 Jan; 28(1):131-9. PubMed ID: 22149770
[TBL] [Abstract][Full Text] [Related]
8. Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine.
Wang XY; Lim-Jurado M; Prepageran N; Tantilipikorn P; Wang de Y
Ther Clin Risk Manag; 2016; 12():585-97. PubMed ID: 27110120
[TBL] [Abstract][Full Text] [Related]
9. An international Delphi study on the burden of allergic rhinoconjunctivitis and urticaria and the role of bilastine among current treatment options.
Church MK; Canonica GW; Kuna P; Maurer M; Mösges R; Novak Z; Papadopoulos NG; Rodriguez Del Rio P;
Expert Rev Clin Immunol; 2023; 19(7):813-820. PubMed ID: 37191185
[TBL] [Abstract][Full Text] [Related]
10. Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria.
Sologuren A; Viñas R; Cordón E; Riesgo SE; Del Mar Forés M; Senán MR; Fernández S; Labeaga L; Ruiz-Miján M
Allergy Asthma Proc; 2018 Jul; 39(4):299-304. PubMed ID: 29559031
[TBL] [Abstract][Full Text] [Related]
11. Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria.
Wolthers OD
Biomed Res Int; 2013; 2013():626837. PubMed ID: 23956994
[TBL] [Abstract][Full Text] [Related]
12. Bilastine: in allergic rhinitis and urticaria.
Carter NJ
Drugs; 2012 Jun; 72(9):1257-69. PubMed ID: 22686617
[TBL] [Abstract][Full Text] [Related]
13. Safety profile of bilastine: 2nd generation H1-antihistamines.
Scaglione F
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1999-2005. PubMed ID: 23242729
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Bilastine on Symptoms of Allergic Rhinitis and Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Abdelshafy AM; Abdallah SY; Hassan AF; Mohamed HA; Kamal NM; Ali ST; Abdelhaleem IA
Am J Rhinol Allergy; 2022 Sep; 36(5):684-694. PubMed ID: 35593100
[TBL] [Abstract][Full Text] [Related]
15. How bilastine is used to treat allergic rhinitis and urticaria in children.
Rodríguez Del Río P; Rodríguez Fernández F; Ballester Asensio E; Tortajada-Girbés M
Immunotherapy; 2022 Jan; 14(1):77-89. PubMed ID: 34850647
[TBL] [Abstract][Full Text] [Related]
16. Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients.
Demonte A; Guanti MB; Liberati S; Biffi A; Fernando F; Fainello M; Pepe P
Eur Rev Med Pharmacol Sci; 2018 Feb; 22(3):820-828. PubMed ID: 29461615
[TBL] [Abstract][Full Text] [Related]
17. Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria.
Sadaba B; Azanza JR; Gomez-Guiu A; Rodil R
Ther Clin Risk Manag; 2013; 9():197-205. PubMed ID: 23667312
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years With Allergic Rhinoconjunctivitis or Urticaria: A Phase 3 Clinical Trial.
Majorek-Olechowska B; Slomskis T; Zollerová L; Martín I; Sánchez C; Gilaberte I; Arranz P;
J Investig Allergol Clin Immunol; 2024 May; ():0. PubMed ID: 38725318
[TBL] [Abstract][Full Text] [Related]
19. Bilastine for the treatment of allergic rhinoconjunctivitis and urticaria: results from an international Delphi study.
Canonica GW; Kuna P; Maurer M; Mösges R; Novak Z; Papadopoulos N; Rodriguez Del Rio P;
Drugs Context; 2024; 13():. PubMed ID: 38742145
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
